Actinogen Medical Ltd has released a press release.
FDA Grants ACW Rare Paediatric Disease Designation in FXS
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- Completion of Entitlement Offer
- Actinogen files new patent applications
- FDA IND Update
- ACW to initiate XanaFX clinical trial in Fragile X syndrome
- R&D Tax Incentive Rebate received of A$2.9 million
Later from Actinogen Medical
- Resignation of Dr Bill Ketelbey as Chief Executive Officer
- ACW raises an addtional $3.55m under a Shortfall Placement
- Actinogen appoints Dr Steven Gourlay as CEO
- Actinogen CEO assumes Managing Director position
- Strategic Update & Teleconference Call Notification
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical